Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1589463 | 0.91 | MAPT (0.50) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL7717015 | 0.91 | MAPT (0.51) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL8631234 | 0.87 | MAPT (0.57) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL16162779 | 0.87 | MAPT (0.47) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL69085 | 0.86 | MAPT (0.46) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL13284234 | 0.86 | MAPT (0.49) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL66583 | 0.86 | MAPT (0.46) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL21642649 | 0.84 | MAPT (0.46) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL6565692 | 0.84 | MAPT (0.65) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL23801874 | 0.83 | MAPT (0.53) | MAPTALDH1A1LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1865379-B1 | Method for resist pattern formation, and process for device prodution | CANON KK (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8129087-B2 | Block copolymer and substrate processing method | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | disclosed |
| US-7651834-B2 | Photosensitive compound, photosensitive composition, method for resist pattern formation, and process for device production | CANON KABUSHIKI KAISHA (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090311637-A1 | BLOCK COPOLYMER AND SUBSTRATE PROCESSING METHOD | CANON KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20070287105-A1 | PHOTOSENSITIVE COMPOUND, PHOTOSENSITIVE COMPOSITION, METHOD FOR RESIST PATTERN FORMATION, AND PROCESS FOR DEVICE PRODUCTION | CANON KABUSHIKI KAISHA (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1865379-A1 | Photosensitive compound, photosensitive composition, method for resist pattern formation, and process for device prodution | Canon Kabushiki Kaisha (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287105-A1 | PHOTOSENSITIVE COMPOUND, PHOTOSENSITIVE COMPOSITION, METHOD FOR RESIST PATTERN FORMATION, AND PROCESS FOR DEVICE PRODUCTION | RER1, C1R, CRY2 | MAPT 2153/4885ALDH1A1 2569/4885LMNA 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.